combined vaccines


Summary: Two or more vaccines in a single dosage form.

Top Publications

  1. Gatchalian S, Reyes M, Bermal N, Chandrasekaran V, Han H, Bock H, et al. A new DTPw-HBV/Hib vaccine: immune memory after primary vaccination and booster dosing in the second year of life. Hum Vaccin. 2008;4:60-6 pubmed
    ..Combined DTPw-HBV and DTPw-HBV/Hib vaccines using new vaccine antigen sources will promote continued supply of combined DTPw-based vaccines to global mass vaccination campaigns. ..
  2. Zinke M, Kappes R, Kindler K, Paulus Koschik A, Goering U, Disselhoff J, et al. Immune memory to hepatitis B virus in 4-9-year old children vaccinated in infancy with four doses of hexavalent DTPa-HBV-IPV/Hib vaccine. Hum Vaccin. 2009;5:592-8 pubmed
    ..The HBV vaccine challenge dose was well tolerated. These studies show that primary and booster vaccination with combined DTPa-HBV-IPV/Hib (Infanrix hexa) induces sustained immune memory against hepatitis B up to age 9 years. ..
  3. Chippaux J, Garba A, Ethevenaux C, Campagne G, de Chabalier F, Djibo S, et al. Immunogenicity, safety, and memory of different schedules of Neisseria meningitidis A/C-diphtheria toxoid conjugate vaccine in infants in Niger. Vaccine. 2004;22:3303-11 pubmed
    ..While responses were lower for serogroup C, hyporesponsiveness was not evident. Men D was well-tolerated. A single Men D dose in infancy appeared to induce memory. ..
  4. Hilton S, Petticrew M, Hunt K. 'Combined vaccines are like a sudden onslaught to the body's immune system': parental concerns about vaccine 'overload' and 'immune-vulnerability'. Vaccine. 2006;24:4321-7 pubmed
    ..role, namely their assessment of the ability of their child's immune system to 'cope' with the challenge of combined vaccines, or to fight the disease...
  5. Kalies H, Grote V, Verstraeten T, Hessel L, Schmitt H, Von Kries R. The use of combination vaccines has improved timeliness of vaccination in children. Pediatr Infect Dis J. 2006;25:507-12 pubmed
    ..Combination vaccines are usually advocated for reducing the number of injections. In Germany, however, the use of combination vaccines has also significantly improved timeliness of immunizations. ..
  6. Freed G, Cowan A, Clark S, Santoli J, Bradley J. Use of a new combined vaccine in pediatric practices. Pediatrics. 2006;118:e251-7 pubmed
    ..Also, the role of the availability of a given vaccine through the Vaccines for Children program is important in its adoption into practice. ..
  7. Lim F, Han H, Jacquet J, Bock H. Primary vaccination of infants against hepatitis B can be completed using a combined hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliomyelitis-Haemophilus influenzae type B vaccine. Ann Acad Med Singapore. 2007;36:801-6 pubmed
    ..We investigated whether a combined hexavalent vaccine, DTPa-HBV-IPV/Hib, could replace the separate administration of DTPa-IPV/Hib and HBV for the final vaccination at 5 months of age (Trial DTPa-HBV-IPV-075)...
  8. Giambi C, Bella A, Barale A, Montù D, Marchisio M, Oddone M, et al. A cohort study to evaluate persistence of hepatitis B immunogenicity after administration of hexavalent vaccines. BMC Infect Dis. 2008;8:100 pubmed publisher
    ..However, long-term persistence of HBV protection after hexavalent vaccines administration should be further evaluated over time. ..
  9. Wu X, Franka R, Svoboda P, Pohl J, Rupprecht C. Development of combined vaccines for rabies and immunocontraception. Vaccine. 2009;27:7202-9 pubmed publisher
    ..The recombinant viruses reacted strongly with the serum from a GonaCon-immunized animal. The GnRH-carrying rabies viruses have significant potential in rabies and animal population control. ..

More Information

Publications106 found, 100 shown here

  1. Stojanov S, Liese J, Bendjenana H, Harzer E, Barrand M, Jow S, et al. Immunogenicity and safety of a trivalent tetanus, low dose diphtheria, inactivated poliomyelitis booster compared with a standard tetanus, low dose diphtheria booster at six to nine years of age. Munich Vaccine Study Group. Pediatr Infect Dis J. 2000;19:516-21 pubmed
    ..Reactions were generally mild and all were temporary. A booster dose of Td-IPV induced in all children seroprotection against tetanus, diphtheria and poliomyelitis. The overall safety profile of the two vaccines was acceptable. ..
  2. Asahi Y, Yoshikawa T, Watanabe I, Iwasaki T, Hasegawa H, Sato Y, et al. Protection against influenza virus infection in polymeric Ig receptor knockout mice immunized intranasally with adjuvant-combined vaccines. J Immunol. 2002;168:2930-8 pubmed
  3. Musa A, Khalil E, Mahgoub F, Elgawi S, Modabber F, Elkadaru A, et al. Immunochemotherapy of persistent post-kala-azar dermal leishmaniasis: a novel approach to treatment. Trans R Soc Trop Med Hyg. 2008;102:58-63 pubmed
    ..Immunochemotherapy probably augmented IFN-gamma production, which induced healing. Leishmanin skin reactivity is a good surrogate marker of cure in persistent PKDL lesions. ..
  4. Collins C, Salt P, McCarthy N, Chantler T, Lane L, Hemme F, et al. Immunogenicity and safety of a low-dose diphtheria, tetanus and acellular pertussis combination vaccine with either inactivated or oral polio vaccine as a pre-school booster in UK children. Vaccine. 2004;22:4262-9 pubmed
    ..The study vaccines containing low-dose diphtheria antigen (Td5aP-IPV and Td5aP + OPV) are immunogenic and have acceptable reactogenicity for use as a pre-school booster vaccine administered concomitantly with MMR. ..
  5. Mishra N, Gupta P, Mahor S, Khatri K, Goyal A, Vyas S. Liposomes as adjuvant for combination vaccines. Indian J Exp Biol. 2007;45:237-41 pubmed
    ..This confirms adjuvantcity of DT vis-a-vis immunogenicity. Thus, carrier mediated cocktail vaccination holds promise for clinical applications. ..
  6. Hessel L, Guenanèche F, Biasio L, Di Marzo R. Reply to "Panico MG, Caporale V, Attena F. Adverse events following hexavalent vaccine (Hexavac): knowledge and information sources". Vaccine. 2007;25:2539-40 pubmed
  7. Schmitt H. A "signal" requires urgent action. Eur J Pediatr. 2005;164:59-60 pubmed
  8. Konishi E, Kosugi S, Imoto J. Dengue tetravalent DNA vaccine inducing neutralizing antibody and anamnestic responses to four serotypes in mice. Vaccine. 2006;24:2200-7 pubmed
  9. Wang K, Guo Y, Zhang Y, Lv K, Sun S. Combined DNA vaccination against three animal viruses elicits decreased immunogenicity of a single plasmid in mice. Vaccine. 2007;25:4429-36 pubmed
    ..05). Taken together, this study reflected the immunogenicity of a single plasmid may be decreased in combined DNA immunization strategy, which still needs to be carefully evaluated before practical application. ..
  10. Gentile A, Bhutta Z, Bravo L, Samy A, Garcia R, Hoosen A, et al. Pediatric disease burden and vaccination recommendations: understanding local differences. Int J Infect Dis. 2010;14:e649-58 pubmed publisher
    ..DTwP-HepB-Hib combination vaccines represent a cost-effective option, with the potential to substantially reduce the burden associated with these diseases by increasing coverage and compliance. ..
  11. Aguilar Betancourt A, Gonzalez Delgado C, Cinza Estévez Z, Martínez Cabrera J, Véliz Ríos G, Alemán Zaldívar R, et al. Safety and immunogenicity of a combined hepatitis B virus-Haemophilus influenzae type B vaccine comprising a synthetic antigen in healthy adults. Hum Vaccin. 2008;4:54-9 pubmed
    ..The present results support phase I-II clinical trial in the target population, two months old healthy infants. ..
  12. Sabio y García J, Farber M, Carrica M, Cravero S, Macedo G, Bigi F, et al. Expression of Babesia bovis rhoptry-associated protein 1 (RAP1) in Brucella abortus S19. Microbes Infect. 2008;10:635-41 pubmed publisher
    ..Therefore, we concluded that B. abortus S19 expressing RAP1 is immunostimulatory and may provide the basis for combined heterologous vaccines for babesiosis and brucellosis. ..
  13. Root Bernstein R. A measles-derived peptide treats and vaccinates against adjuvant arthritis. Autoimmun Rev. 2009;8:405-9 pubmed publisher
    ..These data suggest the possibility of developing novel therapeutic vaccines against some forms of arthritis. ..
  14. Navas E, Salleras L, Gisbert R, Dominguez A, Bruguera M, Rodriguez G, et al. Efficiency of the incorporation of the hepatitis A vaccine as a combined A+B vaccine to the hepatitis B vaccination programme of preadolescents in schools. Vaccine. 2005;23:2185-9 pubmed
    ..98) the net present value of the programme was positive (+533,708) and the benefit-cost ratio was 2.58. If the estimated disease incidence were reduced by half, the programme would still be efficient. ..
  15. Ishikawa T, Takasaki T, Kurane I, Nukuzuma S, Kondo T, Konishi E. Co-immunization with West Nile DNA and inactivated vaccines provides synergistic increases in their immunogenicities in mice. Microbes Infect. 2007;9:1089-95 pubmed
    ..1 microg induced a titer of 1:40 at a 90% plaque reduction 6 or 9 weeks after immunization. Both IgG1 and IgG2a antibodies were induced in mice by co-immunization with the DNA and protein vaccines. ..
  16. Beran J, Kervyn D, Wertzova V, Hobzova L, Tichy P, Kuriyakose S, et al. Comparison of long-term (10 years) immunogenicity of two- and three-dose regimens of a combined hepatitis A and B vaccine in adolescents. Vaccine. 2010;28:5993-7 pubmed publisher
    ..Hence, with respect to long-term antibody persistence, the two-dose schedule of the combined HAB vaccine Adult formulation is an effective alternative to the conventional three-dose schedule of the Paediatric formulation in adolescents. ..
  17. Wu Y, Zhu R, Xu L, Li Y, Li S, Yu H, et al. A novel combined vaccine based on monochimeric VLP co-displaying multiple conserved epitopes against enterovirus 71 and varicella-zoster virus. Vaccine. 2017;35:2728-2735 pubmed publisher
    ..Collectively, our study not only demonstrated that HBc-V/1/2 is a promising candidate combined vaccine for HFMD and Chicken pox but also provides a novel strategy for the design of combined vaccines.
  18. Massa H, Cripps A, Lehmann D. Otitis media: viruses, bacteria, biofilms and vaccines. Med J Aust. 2009;191:S44-9 pubmed
    ..Vaccine development is a key future direction for reducing the world burden of otitis media, but requires polymicrobial formulation and ongoing monitoring and modification to ensure sustained reduction in disease burden. ..
  19. Hosangadi D, Smith P, Kaslow D, Giersing B. WHO consultation on ETEC and Shigella burden of disease, Geneva, 6-7th April 2017: Meeting report. Vaccine. 2018;: pubmed publisher
    ..iterations, has led to debate as to whether investment in development of stand-alone vaccines, rather than combined vaccines, is warranted from cost-effectiveness and vaccine impact perspectives...
  20. Zangwill K, Eriksen E, Lee M, Lee J, Marcy S, Friedland L, et al. A population-based, postlicensure evaluation of the safety of a combination diphtheria, tetanus, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine in a large managed care organization. Pediatrics. 2008;122:e1179-85 pubmed publisher
  21. Kramer E, Hofmann C, Smith P, Shiffman M, Sterling R. Response to hepatitis A and B vaccine alone or in combination in patients with chronic hepatitis C virus and advanced fibrosis. Dig Dis Sci. 2009;54:2016-25 pubmed publisher
  22. Luo J, Shi H, Tan Y, Niu X, Long T, Zhao J, et al. Two potential recombinant rabies vaccines expressing canine parvovirus virion protein 2 induce immunogenicity to canine parvovirus and rabies virus. Vaccine. 2016;34:4392-8 pubmed publisher
    ..Together, this study showed that recombinant RABVs expressing VP2 induced protective immune responses to RABV and CPV. Therefore, rHEP-VP2 and rHEP-dG-VP2 might be potential combined vaccines for RABV and CPV.
  23. Pawłowska M, Halota W, Kozielewicz D. [Combined vaccine against hepatitis A and B]. Przegl Epidemiol. 2004;58 Suppl 1:66-70 pubmed
  24. Baize S. A single shot against Ebola and Marburg virus. Nat Med. 2005;11:720-1 pubmed
  25. Höhler T, Groeger Bicanic G, Hoet B, Stoffel M. Antibody persistence and immune memory elicited by combined hepatitis A and B vaccination in older adults. Vaccine. 2007;25:1503-8 pubmed
    ..A booster vaccination was offered to those who had responded to the first vaccination but then lost protective levels of anti-HBs. An anamnestic response was observed in all cases. ..
  26. Zepp F, Schmitt H, Cleerbout J, Verstraeten T, Schuerman L, Jacquet J. Review of 8 years of experience with Infanrix hexa (DTPa-HBV-IPV/Hib hexavalent vaccine). Expert Rev Vaccines. 2009;8:663-78 pubmed publisher
    ..g., pneumococcal conjugate vaccine). Additional issues surrounding the use of hexavalent vaccines are also reviewed. ..
  27. Ehrenfeld E, Modlin J, Chumakov K. Future of polio vaccines. Expert Rev Vaccines. 2009;8:899-905 pubmed publisher
    ..Combination products containing inactivated poliovirus vaccine and other protective antigens should become part of routine childhood immunizations around the world. ..
  28. Fletcher M, Fabre P, Debois H, Saliou P. Vaccines administered simultaneously: directions for new combination vaccines based on an historical review of the literature. Int J Infect Dis. 2004;8:328-38 pubmed
    ..Nevertheless, complex issues such as necessity, feasibility, or affordability will ultimately determine if any one of these becomes a combination vaccine. ..
  29. Usonis V, Meriste S, Bakasenas V, Lutsar I, Collard F, Stoffel M, et al. Immunogenicity and safety of a combined hepatitis A and B vaccine administered concomitantly with either a measles-mumps-rubella or a diphtheria-tetanus-acellular pertussis-inactivated poliomyelitis vaccine mixed with a Haemophilus influenzae type b . Vaccine. 2005;23:2602-6 pubmed
    ..All vaccines were well tolerated. ..
  30. Maeda Y, Hatta M, Takada A, Watanabe T, Goto H, Neumann G, et al. Live bivalent vaccine for parainfluenza and influenza virus infections. J Virol. 2005;79:6674-9 pubmed
  31. Makoschey B, Bielsa J, Oliviero L, Roy O, Pillet F, Dufe D, et al. Field efficacy of combination vaccines against bovine respiratory pathogens in calves. Acta Vet Hung. 2008;56:485-93 pubmed publisher
    ..The mortality rates for the groups vaccinated with the live vaccine (1.3% and 7.8%) were similar to the unvaccinated controls. In summary, these data demonstrate the efficacy of the inactivated vaccine under field conditions. ..
  32. Cai H, Hu X, Yu D, Li S, Tian X, Zhu Y. Combined DNA vaccine encapsulated in microspheres enhanced protection efficacy against Mycobacterium tuberculosis infection of mice. Vaccine. 2005;23:4167-74 pubmed
  33. Finn A, Heath P. Conjugate vaccines. Arch Dis Child. 2005;90:667-9 pubmed
  34. Hua L, Hongtao H, Shunqin W, Jinping G, Jiandong C, Zhaoliang L, et al. Simultaneous vaccination of Chinese applicants for a United States immigrant visa. Travel Med Infect Dis. 2008;6:130-6 pubmed publisher
    ..Our data suggest that more Chinese people should be encouraged to receive simultaneous vaccination if the time is limited so as to reduce the risk of vaccine-preventable diseases. ..
  35. Marshall H, Nolan T, Diez Domingo J, Rombo L, Sokal E, Mares J, et al. Long-term (5-year) antibody persistence following two- and three-dose regimens of a combined hepatitis A and B vaccine in children aged 1-11 years. Vaccine. 2010;28:4411-5 pubmed publisher
    ..All subjects mounted a vigorous immune response to the challenge indicating the presence of immunological memory to HBV. ..
  36. Steel J, Burmakina S, Thomas C, Spackman E, Garcia Sastre A, Swayne D, et al. A combination in-ovo vaccine for avian influenza virus and Newcastle disease virus. Vaccine. 2008;26:522-31 pubmed
    ..We propose that this virus has potential as a safe in-ovo live, attenuated, bivalent avian influenza and Newcastle disease virus vaccine. ..
  37. Whaley M, Sampson J, Johnson S, Rajam G, Stinson Parks A, Holder P, et al. Concomitant administration of recombinant PsaA and PCV7 reduces Streptococcus pneumoniae serotype 19A colonization in a murine model. Vaccine. 2010;28:3071-5 pubmed publisher
    ..From these mouse studies, co-administering pneumococcal antigens appear to expand coverage and reduce colonization against a non-PCV7 serotype without inhibiting immunogenicity to other serotypes. ..
  38. Agnolon V, Bruno C, Galletti B, Mori E, Ugozzoli M, Pergola C, et al. Multiplex immunoassay for in vitro characterization of acellular pertussis antigens in combination vaccines. Vaccine. 2016;34:1040-6 pubmed publisher
    ..The current study could further be considered as a model to set up in vitro potency assays thus supporting the replacement of animal tests accordingly to the 3Rs concept. ..
  39. Stojanov S, Liese J, Belohradsky B, Vandermeulen C, Hoppenbrouwers K, van der Wielen M, et al. Administration of hepatitis A vaccine at 6 and 12 months of age concomitantly with hexavalent (DTaP-IPV-PRP approximately T-HBs) combination vaccine. Vaccine. 2007;25:7549-58 pubmed
    ..A schedule of two doses of HA vaccine, 6 months apart beginning at 6 months of age is highly immunogenic and well tolerated when administered alone or concomitantly with HV vaccine at 6 and 12 months of age. ..
  40. Elicker S, Sipos W. Compatibility of a combined vaccination against Haemophilus parasuis and porcine reproductive and respiratory syndrome virus. Berl Munch Tierarztl Wochenschr. 2009;122:354-7 pubmed
    ..However, the study did not address the key outcome of combined vaccination, namely immunogenic power. Therefore, further immunological studies are warranted. ..
  41. Mazzola T, Da Silva M, Moreno Y, Lima S, Carniel E, Morcillo A, et al. Robust gammadelta+ T cell expansion in infants immunized at birth with BCG vaccine. Vaccine. 2007;25:6313-20 pubmed
    ..The results suggested that the combined BCG and Hepatitis B vaccine was as immunogenic as BCG separated from Hepatitis B vaccine. ..
  42. Baraldo K, Mori E, Bartoloni A, Norelli F, Grandi G, Rappuoli R, et al. Combined conjugate vaccines: enhanced immunogenicity with the N19 polyepitope as a carrier protein. Infect Immun. 2005;73:5835-41 pubmed
    ..Taken together, these data show that the N19 polyepitope represents a strong and valid option for the generation of improved or new combined glycoconjugate vaccines. ..
  43. Tejedor J, Omeñaca F, Garcia Sicilia J, Esporrín C, Molina V, Mares J, et al. Antibody persistence after primary vaccination with a hexavalent DTPa-HBV-IPV/HiB vaccine coadministered with a meningococcal C-CRM197 vaccine and response to a DTPa-IPV/HiB booster at 18 months of age. Pediatr Infect Dis J. 2006;25:943-5 pubmed
    ..6% (diphtheria, tetanus, polio and polyribosylribitol phosphate) after booster vaccination. The booster was well-tolerated (fever >39.5 degrees C after <2% of doses; large swelling reactions after 6.3% of doses). ..
  44. Lee G, Lorick S, Pfoh E, Kleinman K, Fishbein D. Adolescent immunizations: missed opportunities for prevention. Pediatrics. 2008;122:711-7 pubmed publisher
    ..Additional strategies are needed to increase the use of preventive services among adolescents and to enable providers to vaccinate adolescents at every opportunity. ..
  45. Aravindaram K, Kuo T, Lan C, Yu H, Wang P, Chen Y, et al. Protective immunity against porcine circovirus 2 in mice induced by a gene-based combination vaccination. J Gene Med. 2009;11:288-301 pubmed publisher
    ..This prime-boost vaccination strategy, using a gene gun for DNA priming and recombinant MVA for boosts, may be an attractive vaccine strategy against PCV2 infection in swine. ..
  46. Wang Y, Chen W, Xu W, Wang X, Liu Y, Wu J, et al. [Safety and immunogenicity of combined hepatitis A and hepatitis B vaccine according to 0 and 6 months schedule in healthy children]. Zhonghua Yu Fang Yi Xue Za Zhi. 2010;44:154-6 pubmed
    ..3 mIU/ml to 3314.3 mIU/ml 1, 6, 7 months after initial dose. The Bilive(TM) combined hepatitis A and hepatitis B vaccine has good safety and immunogenicity in healthy children who had preexisting immunity to hepatitis B virus. ..
  47. Santangelo M, McIntosh D, Bigi F, Armoa G, Campos A, Ruybal P, et al. Mycobacterium bovis BCG as a delivery system for the RAP-1 antigen from Babesia bovis. Vaccine. 2007;25:1104-13 pubmed
    ..bovis and encourage further work on the application of rBCG to the development of Babesia vaccines. ..
  48. Lagos R, Munoz A, Levine M, Watson W, Chang I, Paradiso P. Immunology of combining CRM(197) conjugates for Streptococcus pneumoniae, Neisseria meningitis and Haemophilus influenzae in Chilean infants. Vaccine. 2009;27:2299-305 pubmed publisher
    ..Overall, interactions of PCV9, MnCC and Hib affected the magnitude (GMC) of the primary antibody responses to some of the antigens, but not the percentage of subjects who achieved protective antibody thresholds. ..
  49. Xiao wen H, Shu han S, Zhen lin H, Jun L, Lei J, Feng juan Z, et al. Augmented humoral and cellular immune responses of a hepatitis B DNA vaccine encoding HBsAg by protein boosting. Vaccine. 2005;23:1649-56 pubmed
    ..Our regimen may thus provide a strategy for developing an improved immunization against HBV and many other pathogens. ..
  50. Griffin K, Bedford R, Townson K, Phillpotts R, Funnell S, Morton M, et al. Protective efficacy of a recombinant plague vaccine when co-administered with another sub-unit or live attenuated vaccine. FEMS Immunol Med Microbiol. 2005;43:425-30 pubmed
    ..This finding might have implications when considering the co-administration of other vaccine combinations. ..
  51. Grimprel E, von Sonnenburg F, Sänger R, Abitbol V, Wolter J, Schuerman L. Combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and polio vaccine (dTpa-IPV) for booster vaccination of adults. Vaccine. 2005;23:3657-67 pubmed
    ..Vaccination coverage of adults is poor and the use of combined vaccines such as dTpa-IPV during vaccination visits, or for wound management, maximizes opportunities for boosting in ..
  52. Duval B, Gilca V, Boulianne N, Deceuninck G, Rochette L, De Serres G. Immunogenicity of two paediatric doses of monovalent hepatitis B or combined hepatitis A and B vaccine in 8-10-year-old children. Vaccine. 2005;23:4082-7 pubmed
    ..This schedule could facilitate a greater vaccine acceptance and the addition of hepatitis A vaccine to existing adolescent universal hepatitis B virus immunization programs. ..
  53. Goldfarb N, Patel N, Clarke J. Improving quality by encouraging providers to use pediatric combination vaccines. Manag Care. 2005;14:3-12 pubmed
  54. Herlihy E, Klein S, Newcomb M, Blog D, Birkhead G. Expansion of adult hepatitis A and B vaccination in STD clinics and other settings in New York State. Public Health Rep. 2007;122 Suppl 2:36-41 pubmed
    ..Intensive promotion expanded hepatitis vaccination to all county STD clinics and other settings where high-risk adults can be vaccinated. ..
  55. Taubitz W, Menckhoff S, Nothdurft H. [A recall system improves vaccination compliance. A post card to combat lagging immunization rates]. MMW Fortschr Med. 2006;148:40 pubmed
  56. Sheehy N, Drubach L. (18)F-FDG uptake at vaccination site. Pediatr Radiol. 2008;38:246 pubmed
  57. Guerra F, Blatter M, Greenberg D, Pichichero M, Noriega F. Safety and immunogenicity of a pentavalent vaccine compared with separate administration of licensed equivalent vaccines in US infants and toddlers and persistence of antibodies before a preschool booster dose: a randomized, clinical trial. Pediatrics. 2009;123:301-12 pubmed publisher
    ..DTaP(5)-IPV-Hib is a suitable replacement for separately administered DTaP, IPV, and Hib vaccines. ..
  58. Berry S, Berry D. Accounting for multiplicities in assessing drug safety: a three-level hierarchical mixture model. Biometrics. 2004;60:418-26 pubmed
    ..We give examples to illustrate our method and we describe its application to other types of problems. ..
  59. Loebermann M, Kollaritsch H, Ziegler T, Rendi Wagner P, Chambonneau L, Dumas R, et al. A randomized, open-label study of the immunogenicity and reactogenicity of three lots of a combined typhoid fever/hepatitis A vaccine in healthy adults. Clin Ther. 2004;26:1084-91 pubmed
    ..The 3 batches of the combined typhoid fever/HAV vaccine administered by dual-chamber bypass syringe were equally well tolerated and effective in healthy adults, and did not differ significantly in terms of GMTs or seroconversion rates. ..
  60. Abdelmagid O, Larson L, Payne L, Tubbs A, Wasmoen T, Schultz R. Evaluation of the efficacy and duration of immunity of a canine combination vaccine against virulent parvovirus, infectious canine hepatitis virus, and distemper virus experimental challenges. Vet Ther. 2004;5:173-86 pubmed
    ..These data support at least a 4-year duration of immunity for these three "core" fractions in the combination vaccine...
  61. Tichmann I, Preidel H, Grunert D, Habash S, Schult R, Maier R, et al. Comparison of the immunogenicity and reactogenicity of two commercially available hexavalent vaccines administered as a primary vaccination course at 2, 4 and 6 months of age. Vaccine. 2005;23:3272-9 pubmed
    ..The responses to tetanus, Hib and pertussis components were similar. The incidences of clinically relevant solicited symptoms, unsolicited symptoms or serious adverse events were low in both groups. ..
  62. Diggle L, Deeks J, Pollard A. Effect of needle size on immunogenicity and reactogenicity of vaccines in infants: randomised controlled trial. BMJ. 2006;333:571 pubmed
    ..Trial registration Current Controlled Trials ISRCTN62032215 []. ..
  63. Yerkovich S, Rowe J, Richmond P, Suriyaarachchi D, Heaton T, Hollams E, et al. Assessment of the potency and potential immunomodulatory effects of the measles mumps rubella and varicella vaccine in infants. Vaccine. 2007;25:1764-70 pubmed
    ..Parallel analyses of cytokine responses to phytohaemagglutinin and tetanus toxoid did not detect any "bystander" effects of the vaccines on systemic immunity. ..
  64. Beran J. [Ten year's experience with combined hepatitis A and B vaccine]. Klin Mikrobiol Infekc Lek. 2008;14:13-4, 16-23 pubmed
    ..This review is dominantly focused on immunogenicity, safety and reactogenicity data of the vaccine, which are available now for more than 10 years. ..
  65. Chevallier B, Vesikari T, Brzostek J, Knuf M, Bermal N, Aristegui J, et al. Safety and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with routine childhood vaccines. Pediatr Infect Dis J. 2009;28:S109-18 pubmed publisher
  66. Marin M, Broder K, Temte J, Snider D, Seward J. Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010;59:1-12 pubmed, which state that use of a combination vaccine generally is preferred over its equivalent component vaccines...
  67. Marshall G. One for all: newer combination vaccines in practice. Pediatr Ann. 2004;33:501-11 pubmed
    ..In addition, there's the pentavalent bovine reassortant rotavirus vaccine (Rotateq) which, although given orally, will further crowd the schedule. The sooner we become comfortable with combination vaccines, the better. ..
  68. Dzierzbicka K, Kołodziejczyk A. [Adjuvants--essential components of new generation vaccines]. Postepy Biochem. 2006;52:204-11 pubmed
    ..g., HSV, HIV, HCV, HBV, HPV, or Helicobacter pylori) and noninfectious diseases as multiple sclerosis, insulin-dependent diabetes, rheumatoid arthritis, allergy and tumors (e.g., melanoma, breast, or colon cancer). ..
  69. Kitchin N, Reynolds D. Response to Berrington JE, et al. "Reduced anti-PRP antibody response to Hib immunisation in pre-term (<32 weeks) UK infants who received inactivated polio (eIPV)" [Vaccine 2007; 25(49): 8206-8]. Vaccine. 2008;26:1405-6 pubmed publisher
  70. Yang O. Retracing our STEP towards a successful CTL-based HIV-1 vaccine. Vaccine. 2008;26:3138-41 pubmed publisher
  71. Kaur S, Handa S. Erythema multiforme following vaccination in an infant. Indian J Dermatol Venereol Leprol. 2008;74:251-3 pubmed
    ..We report here a case of a two month-old infant with lesions of erythema multiforme minor appearing after two weeks following vaccination for DPT, Hepatitis B and influenza. ..
  72. Esteghamati A, Gouya M, Keshtkar A, Mahoney F. Relationship between occurrence of Guillain-Barre syndrome and mass campaign of measles and rubella immunization in Iranian 5-14 years old children. Vaccine. 2008;26:5058-61 pubmed publisher
    ..According to our results, there was no increase in GBS Incidence in the 4 weeks national Immunization campaign and 6 weeks after it in comparison to other 10 weeks periods before or after this time period. ..
  73. Socan M, Frelih T, Janet E, Petras T, Peternelj B. Reactions after pneumococcal vaccine alone or in combination with influenza vaccine. Vaccine. 2004;22:3087-91 pubmed
    ..Local reactions were reported by 358 (41.6%) participants, but they were mild and soon subsided. No serious reactions were reported. pneumococcal and influenza vaccine can be safely administered simultaneously. ..
  74. Lugoboni F, Quaglio G, Pajusco B, Civitelli P, Romano L, Bossi C, et al. Immunogenicity, reactogenicity and adherence to a combined hepatitis A and B vaccine in illicit drug users. Addiction. 2004;99:1560-4 pubmed
    ..This study suggests that DUs who are HAV/HBV-negative could be vaccinated with combined vaccine. ..
  75. Chianese Bullock K, Pressley J, Garbee C, Hibbitts S, Murphy C, Yamshchikov G, et al. MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma. J Immunol. 2005;174:3080-6 pubmed
    ..Cancer-testis Ags are expressed in multiple types of cancer; thus the MAGE-A1(96-104) and MAGE-A10(254-262) peptides may be considered for inclusion in vaccines against cancers of other histologic types, in addition to melanoma. ..
  76. Halperin S, Tapiero B, Diaz Mitoma F, Law B, Hoffenbach A, Zappacosta P, et al. Safety and immunogenicity of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 3, 4, and 12-14 months of age. Vaccine. 2009;27:2540-7 pubmed publisher
    ..All vaccine formulations were well tolerated. The three PRP-OMPC formulations met prespecified immunogenicity criteria, and the one with the lowest PRP-OMPC concentration was selected for further optimization of immunogenicity. ..
  77. Knuf M, Szenborn L, Moro M, Petit C, Bermal N, Bernard L, et al. Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV). Pediatr Infect Dis J. 2009;28:S97-S108 pubmed publisher
    ..No evidence of negative interference on the immune response to any of the coadministered vaccine antigens was observed when compared with the current routine practice of 7vCRM coadministration. ..
  78. Bae K, Choi J, Jang Y, Ahn S, Hur B. Innovative vaccine production technologies: the evolution and value of vaccine production technologies. Arch Pharm Res. 2009;32:465-80 pubmed publisher
    ..These at-risk groups include infants, the elderly and immunocompromized individuals, as well as people living in developing countries or emerging economies. ..
  79. Kitchin N, Southern J, Morris R, Borrow R, Fiquet A, Boisnard F, et al. Antibody persistence in UK pre-school children following primary series with an acellular pertussis-containing pentavalent vaccine given concomitantly with meningococcal group C conjugate vaccine, and response to a booster dose of an acellular pertus. Vaccine. 2009;27:5096-102 pubmed publisher
    ..Reactogenicity of Repevax was acceptable and consistent with previous experience. ..
  80. Suarez E, Asturias E, Hilbert A, Herzog C, Aeberhard U, Spyr C. A fully liquid DTPw-HepB-Hib combination vaccine for booster vaccination of toddlers in El Salvador. Rev Panam Salud Publica. 2010;27:117-24 pubmed
  81. Lackmann G. Comparative investigation of the safety of hexavalent vaccines for primary scheduled infant immunizations in Germany over a time period of 2 years. Med Sci Monit. 2004;10:PI96-8 pubmed
    ..1%, respectively. The safety of Priorix and Infanrix hexa in particular could be established. Hexavalent vaccines can be recommended for introduction in all European countries for primary scheduled infant immunizations. ..
  82. Danek J, Czajka H, Jawor Bugajska M, Kruk W. [Vaccinations as a cause of children hospitalisation in Neuroinfection Department of the John Paul II Hospital in Cracow between 2002--2004]. Przegl Epidemiol. 2004;58 Suppl 1:117-22 pubmed
    ..However the most often to cause AEFI was vaccination DTP with full-cell pertussis component. ..
  83. Halperin S, Tapiero B, Law B, Diaz Mitoma F, Duval B, Langley J, et al. Interchangeability of two diphtheria and tetanus toxoids, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b conjugate vaccines as a fourth dose in 15-20-month-old toddlers. Vaccine. 2006;24:4017-23 pubmed
    ..3 versus 1134.2 reciprocal dilution). A booster dose of Infanrix-IPV-Hib after three priming doses of Pentacel is well-tolerated and immunogenic in 15-20-month-old toddlers and can be used interchangeably. ..
  84. Van der Wielen M, Van Damme P, Chlibek R, Smetana J, von Sonnenburg F. Hepatitis A/B vaccination of adults over 40 years old: comparison of three vaccine regimens and effect of influencing factors. Vaccine. 2006;24:5509-15 pubmed
    ..In conclusion, Twinrix induced superior hepatitis B SP rates and similar hepatitis A S+ rates compared to concomitant administration of monovalent vaccines in subjects aged >40 years. ..
  85. Wildman B, Perrett T, Abutarbush S, Guichon P, Pittman T, Booker C, et al. A comparison of 2 vaccination programs in feedlot calves at ultra-high risk of developing undifferentiated fever/bovine respiratory disease. Can Vet J. 2008;49:463-72 pubmed
    ..86 CDN/animal in the MLV3-BT2 group. This study demonstrates that it is more cost effective to use an MLV3-BT2 vaccination program than a MLV4-BT1 vaccination program in feedlot calves at ultra-high risk of developing UF/BRD...
  86. Jackowska T, Grzelczyk Wielgórska M. [The effectiveness and safety of vaccine against meningococci group C conjugated with tetanus toxoid co-administrated with different vaccines--literature review]. Przegl Epidemiol. 2010;64:99-103 pubmed
    ..No data about co-administration of NeisVac-C vaccine with influenza vaccine, varicella, HPV vaccine have been found. ..
  87. Huebner R, Nicol M, Mothupi R, Kayhty H, Mbelle N, Khomo E, et al. Dose response of CRM197 and tetanus toxoid-conjugated Haemophilus influenzae type b vaccines. Vaccine. 2004;23:802-6 pubmed
    ..Our data suggest that doses of these vaccines of > or =1.25 microg may be sufficient to stimulate an immune response that offers both short and longer term protection from invasive Hib disease. ..
  88. Jones S, Feldmann H, Stroher U, Geisbert J, Fernando L, Grolla A, et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med. 2005;11:786-90 pubmed
    ..No evidence of EBOV or MARV replication was detected in any of the protected animals after challenge. Our data suggest that these vaccine candidates are safe and highly efficacious in a relevant animal model. ..
  89. Csepregi A, Treiber G, Rocken C, Malfertheiner P. Acute exacerbation of autoimmune hepatitis induced by Twinrix. World J Gastroenterol. 2005;11:4114-6 pubmed
  90. Meriste S, Lutsar I, Tamm E, Willems P. Safety and immunogenicity of a primary course and booster dose of a combined diphtheria, tetanus, acellular pertussis, hepatitis B and inactivated poliovirus vaccine. Scand J Infect Dis. 2006;38:350-6 pubmed
    ..Both vaccine regimens were well tolerated and immunogenic, however the combined administration has the advantage of being administered as a single injection. ..
  91. Saoud A, el Sayed M, Zedan S, Wasel M, El Sawalhy A. Evaluation of A live trivalent vaccine for infectious bovine rhinotracheitis virus, para-influenza type-3 virus and Pasteurella multocida in calves. Egypt J Immunol. 2004;11:101-8 pubmed
    ..It is concluded that the prepared vaccine may be useful for controlling Bovine respiratory disease in calves. ..
  92. Shlomovitz E, Davies W, Cairns E, Brintnell W, Goldszmidt M, Dresser G. Severe necrotizing pancreatitis following combined hepatitis A and B vaccination. CMAJ. 2007;176:339-42 pubmed
    ..This report serves to alert physicians to the possible development of necrotizing pancreatitis after vaccination. ..